We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 21, 2018

In High Risk Patients, Canagliflozin Reduces Risk of Cardiovascular Death and Heart Failure Hospitalization

Circulation

 

Additional Info

Circulation
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Circulation 2018 Mar 11;[EPub Ahead of Print], K Rådholm, G Figtree, V Perkovic, SD Solomon, KW Mahaffey, D de Zeeuw, G Fulcher, TD Barrett, W Shaw, M Desai, DR Matthews, B Neal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading